{'fraction_non_alphanumeric': 0.032665964172813484, 'fraction_numerical': 0.02107481559536354, 'mean_word_length': 4.621301775147929, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 2, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Casirivimab and imdevimab (REGEN-COV) for post-exposure prophylaxis of COVID-19.

The investigational monoclonal antibodies casirivimab and imdevimab (REGEN-COV - Regeneron) have been available in the US under an Emergency Use Authorization (EUA) since late 2020 for use together to treat mild to moderate COVID-19 in persons >12 years old who weigh >40 kg and are at high risk of progression to severe disease or hospitalization. The FDA has now expanded this EUA to allow use of the antibodies together for post-exposure prophylaxis of COVID-19 in such persons, if they are not fully vaccinated against COVID-19 or are unlikely to have an adequate immune response to full-va.ccination and have been in close contact with a SARS-CoV-2-infected individual or are likely to be exposed to SARS-CoV-2 in the setting of an institutional outbreak. Casirivimab and imdevimab are the first drugs to receive an EUA for post-exposure prophylaxis of COVID-19.